APD schedules and clinical results.

Area of Science:

• Nephrology
• Biomedical Engineering

Background:

• Continuous peritoneal dialysis (PD) is a crucial treatment for end-stage renal disease.
• Different automated peritoneal dialysis (APD) schedules exist, each with unique clinical effects.
• Sodium (Na) removal is often lower with APD compared to continuous ambulatory peritoneal dialysis (CAPD).

Purpose of the Study:

• To analyze the clinical effects of various APD schedules.
• To identify optimal parameters for APD therapy, focusing on maximizing small molecule clearance and preserving residual renal function.
• To introduce and evaluate a novel APD schedule, 'BreakPoint-APD'.

Main Methods:

• Review of clinical studies comparing APD and CAPD.
• Analysis of factors influencing peritoneal small molecule clearances, including dialysate flow rate and intraperitoneal volume.
• Evaluation of 'BreakPoint-APD' schedule, which adapts to individual patient drain profiles.

Main Results:

• APD shows lower Na removal than CAPD, necessitating continuous therapy for residual renal function.
• Small molecule clearance is primarily determined by hourly dialysate flow rate, with optimal rates around 3 L/h for average patients.
• The 'BreakPoint-APD' schedule increased clearances by approximately 10% compared to tidal and CCPD, while reducing nocturnal alarms.

Conclusions:

• Optimizing APD schedules, particularly by adapting to individual drain profiles, can significantly enhance treatment efficacy.
• Future advancements in cycler technology will likely further simplify APD use and improve patient outcomes.
• BreakPoint-APD represents a promising advancement in automated peritoneal dialysis, offering improved clearance and patient comfort.